[1]
C. J. Miller, MS, R. C. Dart, MD, N. P. Katz, MD, MS, and L. R. Webster, MD, FACPM, FASAM, “Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids”, J of Opioid Management, vol. 13, no. 6, pp. 379–389, Dec. 2017.